JP2020078318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020078318A5 JP2020078318A5 JP2020015937A JP2020015937A JP2020078318A5 JP 2020078318 A5 JP2020078318 A5 JP 2020078318A5 JP 2020015937 A JP2020015937 A JP 2020015937A JP 2020015937 A JP2020015937 A JP 2020015937A JP 2020078318 A5 JP2020078318 A5 JP 2020078318A5
- Authority
- JP
- Japan
- Prior art keywords
- isfahan
- virus
- antigen
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022095401A JP2022126723A (ja) | 2014-03-01 | 2022-06-14 | 組換えイスファハンウイルスベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946734P | 2014-03-01 | 2014-03-01 | |
| US61/946,734 | 2014-03-01 | ||
| JP2016555578A JP2017508465A (ja) | 2014-03-01 | 2015-02-27 | 組換えイスファハンウイルスベクター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555578A Division JP2017508465A (ja) | 2014-03-01 | 2015-02-27 | 組換えイスファハンウイルスベクター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022095401A Division JP2022126723A (ja) | 2014-03-01 | 2022-06-14 | 組換えイスファハンウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020078318A JP2020078318A (ja) | 2020-05-28 |
| JP2020078318A5 true JP2020078318A5 (enExample) | 2021-03-18 |
| JP7454393B2 JP7454393B2 (ja) | 2024-03-22 |
Family
ID=54055975
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555578A Pending JP2017508465A (ja) | 2014-03-01 | 2015-02-27 | 組換えイスファハンウイルスベクター |
| JP2020015937A Active JP7454393B2 (ja) | 2014-03-01 | 2020-02-03 | 組換えイスファハンウイルスベクター |
| JP2022095401A Pending JP2022126723A (ja) | 2014-03-01 | 2022-06-14 | 組換えイスファハンウイルスベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555578A Pending JP2017508465A (ja) | 2014-03-01 | 2015-02-27 | 組換えイスファハンウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022095401A Pending JP2022126723A (ja) | 2014-03-01 | 2022-06-14 | 組換えイスファハンウイルスベクター |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9932564B2 (enExample) |
| EP (1) | EP3113795B1 (enExample) |
| JP (3) | JP2017508465A (enExample) |
| KR (1) | KR102416194B1 (enExample) |
| CN (1) | CN106794240A (enExample) |
| AU (1) | AU2015225553B2 (enExample) |
| CA (1) | CA2941261A1 (enExample) |
| DK (1) | DK3113795T3 (enExample) |
| ES (1) | ES2749381T3 (enExample) |
| IL (2) | IL247545B (enExample) |
| MX (1) | MX369776B (enExample) |
| SG (1) | SG11201607287XA (enExample) |
| WO (1) | WO2015134332A2 (enExample) |
| ZA (1) | ZA201606036B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| KR20200096904A (ko) * | 2017-09-15 | 2020-08-14 | 오하이오 스테이트 이노베이션 파운데이션 | 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법 |
| EP3823654B1 (en) * | 2018-07-17 | 2024-02-14 | Yale University | Methods for treatment of cancer using chikungunya-vsv chimeric virus |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| CN115612674A (zh) * | 2021-07-14 | 2023-01-17 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DK1605971T3 (da) * | 2003-03-26 | 2010-08-16 | Wyeth Llc | Immunogene sammensætninger og fremgangsmåder |
| NZ550150A (en) * | 2004-04-09 | 2009-05-31 | Wyeth Corp | Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| CN101087886B (zh) * | 2004-04-09 | 2013-07-17 | 惠氏公司 | 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒 |
| EP2064229B1 (en) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| WO2009019612A2 (en) * | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| US8815564B2 (en) * | 2008-03-14 | 2014-08-26 | Sanofi Pasteur Biologics, Llc | Replication-defective flavivirus vaccines and vaccine vectors |
| WO2010105347A1 (en) * | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| ES2533345T3 (es) * | 2009-06-08 | 2015-04-09 | The University Of Western Ontario | Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización |
| DK2772265T3 (en) * | 2010-05-14 | 2018-04-30 | Univ Oregon Health & Science | Recombinant HCMV and RHCMV vectors and uses thereof |
| US20130095556A1 (en) * | 2011-09-21 | 2013-04-18 | International Aids Vaccine Initiative | Novel vesicular stomatitis virus and virus rescue system |
-
2015
- 2015-02-27 CN CN201580026511.3A patent/CN106794240A/zh active Pending
- 2015-02-27 SG SG11201607287XA patent/SG11201607287XA/en unknown
- 2015-02-27 MX MX2016011300A patent/MX369776B/es active IP Right Grant
- 2015-02-27 JP JP2016555578A patent/JP2017508465A/ja active Pending
- 2015-02-27 CA CA2941261A patent/CA2941261A1/en active Pending
- 2015-02-27 EP EP15758863.3A patent/EP3113795B1/en active Active
- 2015-02-27 US US15/122,695 patent/US9932564B2/en active Active
- 2015-02-27 ES ES15758863T patent/ES2749381T3/es active Active
- 2015-02-27 AU AU2015225553A patent/AU2015225553B2/en not_active Ceased
- 2015-02-27 WO PCT/US2015/018156 patent/WO2015134332A2/en not_active Ceased
- 2015-02-27 DK DK15758863.3T patent/DK3113795T3/da active
- 2015-02-27 KR KR1020167027395A patent/KR102416194B1/ko active Active
-
2016
- 2016-08-30 IL IL247545A patent/IL247545B/en unknown
- 2016-08-31 ZA ZA2016/06036A patent/ZA201606036B/en unknown
-
2020
- 2020-02-03 JP JP2020015937A patent/JP7454393B2/ja active Active
-
2022
- 2022-01-31 IL IL290258A patent/IL290258A/en unknown
- 2022-06-14 JP JP2022095401A patent/JP2022126723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020078318A5 (enExample) | ||
| US10646557B2 (en) | Vaccine composition | |
| Cohen et al. | Modulating the immune response to genetic immunization | |
| US9630996B2 (en) | Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins | |
| WO2015106697A1 (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
| AU2017297610A1 (en) | Compositions and methods for alphavirus vaccination | |
| JP2010500399A5 (enExample) | ||
| JP2008508866A5 (enExample) | ||
| JP2005537800A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| WO2003031602A1 (en) | The oncolytic microorganisms expressing hsp and uses thereof | |
| Ansardi et al. | Characterization of poliovirus replicons encoding carcinoembryonic antigen | |
| CA2419822A1 (en) | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization | |
| JP2025094154A5 (enExample) | ||
| JP2021506300A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物 | |
| Gupta et al. | Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag | |
| US11160857B2 (en) | Multivalent enterovirus vaccine compositions and uses related thereto | |
| CN118791633A (zh) | 一种预防病毒性心肌炎的细菌样颗粒疫苗及其制备方法和应用 | |
| CN105198982B (zh) | 基于il-6的抗原表位及其应用 | |
| CN115969965A (zh) | 一种结核分枝杆菌的重组dna疫苗及其制备方法 | |
| Demberg et al. | Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge | |
| CN115850520A (zh) | 新型结核病亚单位疫苗al的制备方法和应用 | |
| Xie et al. | Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency | |
| CN116640736A (zh) | 重组人4型腺病毒载体的SARS-CoV-2疫苗候选株的构建及其应用 | |
| Ndi et al. | Adenoviral vectors in veterinary vaccine development: potential for further development |